TABLE 2.
Characteristics of patients measured liver stiffness using SWE at baseline and after 48 weeks of pemafibrate treatment.
| n = 51 | Baseline | 48 weeks | P-value |
| Male/female | 35/16 | ||
| Age (years) | 49.4±14.3 | ||
| Body weight (kg) | 76.1±12.3 | 75.4±12.8 | ns |
| Hypertension (%) | 10 | ||
| Diabetes mellitus (%) | 8 | ||
| AST (IU/L) | 53.3 ± 35.6 | 31.7 ± 18.2 | <0.0001 |
| ALT (IU/L) | 90.7 ± 63.1 | 40.3 ± 40.0 | <0.0001 |
| γ-GTP (IU/L) | 99.7 ± 94.9 | 44.3 ± 46.8 | <0.0001 |
| TG (mg/dL) | 227.6 ± 152.8 | 123.2 ± 67.8 | <0.0001 |
| LDL-C (mg/dL) | 133.6 ± 25.8 | 114.5 ± 25.4 | <0.0001 |
| HDL-C (mg/dL) | 50.1 ± 14.0 | 53.6 ± 13.6 | <0.05 |
| Cr (mg/dL) | 0.82 ± 0.17 | 0.85 ± 0.18 | <0.001 |
| Plt (×104/μL) | 25.4 ± 5.5 | 27.1 ± 6.5 | <0.005 |
| FIB-4 | 1.25 ± 1.16 | 1.06 ± 0.74 | <0.05 |
SWE, shear wave elastography; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Cr, creatinine; Plt, platelet; FIB-4, fibrosis-4.